NCT01225237已完成4 期
Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 296
- 主要终点
- Responder rate of stool form normalization
研究概览
简要总结
A study to verify the superiority of ramosetron hydrochloride (Irribow Tablets) to placebo for male patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients meeting the Rome III Diagnostic Criteria
- •Loose (mushy) or watery stools within the last 3 months
排除标准
- •Patients with a history of surgical resection of the stomach, small intestine or large intestine
- •Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)
- •Patients with a history or current diagnosis of colitis ischemic
- •Patients with a current diagnosis of enteritis infectious
- •Patients with a current diagnosis of hyperthyroidism or hypothyroidism
- •Patients who are currently participating in another clinical trial (including a post-marketing clinical study) or those who participated in another clinical trial (including a post-marketing clinical study) within 12 weeks before the study
- •Patients with a history or current diagnosis of malignant tumor
- •Patients with a history of abuse of drugs or alcohol within 1 year or those who are currently abusing them
研究组 & 干预措施
ramosetron group
Experimental
干预措施: Ramosetron (Drug)
Placebo group
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Responder rate of stool form normalization
时间窗: For 4 weeks
次要结局
- Responder rate of patients reported global assessment of relief of IBS symptoms(For 4 weeks)
- Responder rate of patients reported assessment of relief of abdominal discomfort and/or pain(For 4 weeks)
- Responder rate of patients reported assessment of improvement of abnormal bowel habits(For 4 weeks)
- Safety assessed by the incidence of adverse events and abnormal values in labo-tests(For 4 weeks)
研究者
相似试验
尚未招募
不适用
Efficacy of ramosetron hydrochloride in male patients with diarrhea-predominant irritable bowel syndromeJPRN-UMIN000006663Shimane University Faculty of Medicine, Department of Gastroenterology and Hepatology200
已完成
4 期
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel SyndromeIrritable Bowel SyndromeNCT00918411Astellas Pharma Inc98
已完成
不适用
Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and VomitingPostoperative Nausea and VomitingNCT01476280Incheon St.Mary's Hospital100
终止
3 期
Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep DisturbanceInsomniaBipolar DisorderNCT00585208Lindner Center of HOPE21
已完成
3 期
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and NauseaVomitingNauseaNCT00272285Astellas Pharma Inc287